Humanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platform.

Pub Date : 2020-11-20 DOI:10.2217/lmt-2020-0018

Huamao M Lin, Xiaoyun Pan, Alyssa Biller, Kyla J Covey, Hui Huang, Rebecca Sugarman, Fatima Scipione, Howard West

{"title":"Humanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platform.","authors":"Huamao M Lin, Xiaoyun Pan, Alyssa Biller, Kyla J Covey, Hui Huang, Rebecca Sugarman, Fatima Scipione, Howard West","doi":"10.2217/lmt-2020-0018","DOIUrl":null,"url":null,"abstract":"Aim: Evaluate real-world patient preferences, experiences and outcomes (health-related quality of life [HRQoL]) from patients with anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) utilizing the ALKConnect Patient Insight Network.Patients & methods: Demographics, disease history/status/treatment, patient preferences and HRQoL (MD Anderson Symptom Inventory lung cancer module, reported as symptom severity and interference) were evaluated for US adults with ALK+ NSCLC.Results: Among 104 patients (median age: 53.0 years, 67.3% female, 40.0% employed), HRQoL and 3-month delay in disease progression were important treatment attributes. Burdensome symptoms included fatigue and disturbed sleep. Symptoms interfered most with work and day-to-day activity. Higher HRQoL was associated with ALK tyrosine kinase inhibitor (TKI) treatment and employment.Conclusion: ALKConnect demonstrated that disease progression, HRQoL, fatigue/sleep, ALK TKIs and employment matter in ALK+ NSCLC.","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0018","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2020-0018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Evaluate real-world patient preferences, experiences and outcomes (health-related quality of life [HRQoL]) from patients with anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) utilizing the ALKConnect Patient Insight Network.

Patients & methods: Demographics, disease history/status/treatment, patient preferences and HRQoL (MD Anderson Symptom Inventory lung cancer module, reported as symptom severity and interference) were evaluated for US adults with ALK+ NSCLC.

Results: Among 104 patients (median age: 53.0 years, 67.3% female, 40.0% employed), HRQoL and 3-month delay in disease progression were important treatment attributes. Burdensome symptoms included fatigue and disturbed sleep. Symptoms interfered most with work and day-to-day activity. Higher HRQoL was associated with ALK tyrosine kinase inhibitor (TKI) treatment and employment.

Conclusion: ALKConnect demonstrated that disease progression, HRQoL, fatigue/sleep, ALK TKIs and employment matter in ALK+ NSCLC.

Abstract Image

查看原文

间变性淋巴瘤激酶阳性非小细胞肺癌的人文生活负担:来自ALKConnect患者洞察网络和研究平台的研究结果

目的:利用ALKConnect患者洞察网络评估间变性淋巴瘤激酶阳性(ALK+)非小细胞肺癌(NSCLC)患者的现实世界患者偏好、经历和结果(健康相关生活质量[HRQoL])。患者和方法:对美国成年ALK+ NSCLC患者的人口统计学、病史/状态/治疗、患者偏好和HRQoL (MD安德森症状量表肺癌模块，报告为症状严重程度和干扰)进行评估。结果:104例患者(中位年龄:53.0岁，67.3%为女性，40.0%为在职)，HRQoL和疾病进展延迟3个月是重要的治疗属性。繁重的症状包括疲劳和睡眠紊乱。症状对工作和日常活动的影响最大。较高的HRQoL与ALK酪氨酸激酶抑制剂(TKI)的治疗和使用有关。结论:ALKConnect表明ALK+ NSCLC的疾病进展、HRQoL、疲劳/睡眠、ALK TKIs和就业相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文